Welcome to Hmobio!Global leader in active molecules.
Find Your Distributors

Select Your Country or Region

 $ USD

For research purposes only. Not for human experiments
You are here:Home-Research Areas-Cancer-Solid Tumors

Request The Product List ofSolid Tumors Solid Tumors

Tumors can be divided into solid tumors and non solid tumors clinically. Solid tumors and tangible tumors can be identified by clinical examination, such as X-ray, CT scan, B-ultrasound, or palpation. Non solid tumors, X-ray, CT scan, B-ultrasound and palpation can not be seen or palpated tumors, such as leukemia in hematologic diseases, belong to non solid tumors.

Cat. No. Product Name CAS No. Information
H9598

Sovilnesib

 		2410796-79-9

AMG-650 is an oral, first in class, selective small molecule inhibitor of KIF18A for treatment of advanced solid tumors.
H9570

Izorlisib

 		1007207-67-1

Izorlisib(CH5132799) is a selective class I PI3K inhibitor. CH5132799 inhibits class I PI3Ks, particularly PI3Kα, with an IC50 of 14 nM.
H9552

Elzovantinib

 		2271119-26-5

Elzovantinib is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.
H9538

Bezuclastinib

 		1616385-51-3

Bezuclastinib (CGT9486,PLX 9486) is a potent inhibitor of c-kit and c-kit D816V 
H9372

Subasumstat

 		1858276-04-6

Subasumstat (TAK-981) is a first in class and selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities.
H9371

Inupadenant hydrochloride

 		2411004-22-1

Inupadenant hydrochloride is a potent and highly selective small molecule antagonist of the A2A receptor that remains active even at the high adenosine concentration found in tumors and that does not cross the blood-brain barrier.

H9368

Zeteletinib mesylate

 		2216753-98-7

Zeteletinib mesylate is an orally, novel highly potent and selective RET kinase inhibitor.
H9367

Zeteletinib

 		2216753-97-6

Zeteletinib is an orally, novel highly potent and selective RET kinase inhibitor.
H9344

Onzigolide

 		778630-77-6

Onzigolide is a chimeric dopamine (DA)-somatostatin (SST) compound with potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors. Studies have shown that chimeric DA-SST compounds are more efficacious than individual DA and/or SST analogues, either alone or combined, in inhibiting secretion from primary cultures of human somatotroph and lactotroph tumor cells; Nonfunctioning pituitary adenomas (NFPAs) express both D2R and SSTR2 and, consequently, may respond to TBR-760. We used a mouse model with the pro-opiomelanocortin (POMC) gene knocked out that spontaneously develops aggressive NFPAs.
H9335

Locnartecan

 		1472614-83-7

Locnartecan is a potential agent for controlling early stage tumor growth for non-small cell lung cancer (NSCLC). PEN-866 is a novel esterase-cleavable conjugate of an HSP90i and a topoisomerase I inhibitor, SN-38.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 HmoBio. All Rights Reserved. Products are only for research use
沪ICP备2020027822号-1